We are live on
!
Find out more
SCM
Shelton Capital Management Portfolio holdings
AUM
$4.57B
1-Year Est. Return
32.26%
This Fund
S&P 500
This Quarter
Est. Return
+10.17%
1 Year Est. Return
+32.26%
3 Year Est. Return
+110.31%
5 Year Est. Return
+153.06%
10 Year Est. Return
+600.84%
AUM
$661M
AUM Growth
+$63.6M
(+11%)
Cap. Flow
+$8.57M
Cap. Flow
% of AUM
1.3%
Top 10 Holdings %
Top 10 Hldgs %
16.59%
Holding
777
New
87
Increased
152
Reduced
160
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axos Financial
AX
|
+$1.14M |
| 2 |
Intercontinental Exchange
ICE
|
+$1.1M |
| 3 |
Exelixis
EXEL
|
+$1.1M |
| 4 |
Tesla
TSLA
|
+$1.09M |
| 5 |
Intel
INTC
|
+$582K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$3.57M |
| 2 |
FLG
Flagstar Bank National Association
FLG
|
+$1.62M |
| 3 |
CELG
Celgene Corp
CELG
|
+$1.59M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$1.54M |
| 5 |
Ametek
AME
|
+$1.25M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.89% |
| 2 | Healthcare | 15% |
| 3 | Financials | 12.41% |
| 4 | Industrials | 10.23% |
| 5 | Energy | 8.65% |
Similar funds
SV
LNWTC
SCM
AG
ANTB
DWM
LPPI
DK
Shelton Capital Management's Q4 2013 Portfolio in Review
As of Q4 2013, Shelton Capital Management held 777 positions worth $661M, up 11% from $598M the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Shelton Capital Management's Q4 2013 filing shows 87 new, 152 increased, 160 reduced and 27 closed positions. Its largest new stake was Axos Financial: 63,596 shares worth $1.25M. The largest sale was BioMarin Pharmaceuticals, an estimated $3.57M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Shelton Capital Management's largest Q4 2013 buy was Axos Financial: 63,596 shares worth $1.25M.
- Shelton Capital Management added most to Tesla in Q4 2013, an estimated $1.09M increase.
- Shelton Capital Management's biggest Q4 2013 reduction was BioMarin Pharmaceuticals, cutting an estimated $3.57M.
- Shelton Capital Management fully exited Ametek in Q4 2013, selling an estimated $1.25M.
- Shelton Capital Management's ten largest holdings make up 17% of its $661M portfolio in Q4 2013.
- Shelton Capital Management opened 87 new positions and closed 27 in Q4 2013.
- Shelton Capital Management's portfolio value rose 11% quarter-over-quarter to $661M.
Based on Shelton Capital Management's 13F filing for Q4 2013, filed 22 Jan 2014.